Abstract
Objectives
To identify candidate imaging biomarkers for early disease progression in glioblastoma multiforme (GBM) patients by analysis of dynamic contrast-enhanced (DCE) MR parameters of non-enhancing T2 high signal intensity (SI) lesions.
Methods
Forty-nine GBM patients who had undergone preoperative DCE MR imaging and received standard treatment were retrospectively included. According to the Response Assessment in Neuro-Oncology criteria, patients were classified into progression (n = 21) or non-progression (n = 28) groups. We analysed the pharmacokinetic parameters of Ktrans, Ve and Vp within non-enhancing T2 high SI lesions of each tumour. The best percentiles of each parameter from cumulative histograms were identified by the area under the receiver operating characteristic curve (AUC) and were compared using multivariate stepwise logistic regression.
Results
For the differentiation of early disease progression, the highest AUC values were found in the 99th percentile of Ktrans (AUC 0.954), the 97th percentile of Ve (AUC 0.815) and the 94th percentile of Vp (AUC 0.786) (all p < 0.05). The 99th percentile of Ktrans was the only significant independent variable from the multivariate stepwise logistic regression (p = 0.002).
Conclusions
We found that the Ktrans of non-enhancing T2 high SI lesions in GBM patients holds potential as a candidate prognostic marker in future prospective studies.
Key Points
• DCE MR imaging provides candidate prognostic marker of GBM after standard treatment.
• Cumulative histogram was applied to include entire non-enhancing T2 high SI lesions.
• The 99th percentile value of Ktrans was the most likely potential biomarker.
Similar content being viewed by others
Abbreviations
- AUC:
-
Area under the receiver operating characteristic curve
- DCE:
-
Dynamic contrast-enhanced
- GBM:
-
Glioblastoma multiforme
- Ktrans:
-
Volume transfer constant
- RANO:
-
Response Assessment in Neuro-Oncology
- Ve:
-
Extravascular extracellular space per unit volume of tissue
- Vp:
-
Blood plasma volume per unit volume of tissue
References
Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22:633–638
Norden AD, Drappatz J, Muzikansky A et al (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92:149–155
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
Barajas RF Jr, Phillips JJ, Parvataneni R et al (2012) Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging. Neuro Oncol 14:942–954
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401
Idoate MA, Diez Valle R, Echeveste J, Tejada S (2011) Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. Neuropathology 31:575–582
Gaspar LE, Fisher BJ, Macdonald DR et al (1992) Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55–57
Jain R (2013) Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications. NMR Biomed 26:1042–1049
Jung SC, Yeom JA, Kim JH et al (2014) Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. Am J Neuroradiol 35:1103–1110
Cao Y, Nagesh V, Hamstra D et al (2006) The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res 66:8912–8917
Jia Z, Geng D, Xie T, Zhang J, Liu Y (2012) Quantitative analysis of neovascular permeability in glioma by dynamic contrast-enhanced MR imaging. J Clin Neurosci 19:820–823
Khalifa J, Tensaouti F, Chaltiel L et al (2016) Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation. Eur Radiol. doi:10.1007/s00330-016-4234-5
Castellano A, Donativi M, Rudà R et al (2016) Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps. Eur Radiol 26:1263–1273
Yoon RG, Kim HS, Kim DY, Hong GS, Kim SJ (2016) Apparent diffusion coefficient parametric response mapping MRI for follow-up of glioblastoma. Eur Radiol 26:1037–1047
Tofts PS, Kermode AG (1991) Measurement of the blood brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357–367
Haacke EM, Filleti CL, Gattu R et al (2007) New algorithm for quantifying vascular changes in dynamic contrast‐enhanced MRI independent of absolute T1 values. Magn Reson Med 58:463–472
Pluim JP, Maintz JA, Viergever M (2003) Mutual-information-based registration of medical images: a survey. IEEE Trans Med Imaging 22:986–1004
Sundar H, Shen D, Biros G, Xu C, Davatzikos C (2007) Robust computation of mutual information using spatially adaptive meshes. Med Image Comput Comput Assist Interv 10:950–958
Jung SC, Choi SH, Yeom JA et al (2013) Cerebral blood volume analysis in glioblastomas using dynamic susceptibility contrast-enhanced perfusion MRI: a comparison of manual and semiautomatic segmentation methods. PLoS One 8, e69323
Tozer DJ, Jäger HR, Danchaivijitr N et al (2007) Apparent diffusion coefficient histograms may predict low‐grade glioma subtype. NMR Biomed 20:49–57
Man MZ, Dyson G, Johnson K, Liao B (2004) Evaluating methods for classifying expression data. J Biopharm Stat 14:1065–1084
Hauck WW, Miike R (1991) A proposal for examining and reporting stepwise regressions. Stat Med 10:711–715
Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65–73
Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF (2005) MR imaging correlates of survival in patients with high-grade gliomas. Am J Neuroradiol 26:2466–2474
Schoenegger K, Oberndorfer S, Wuschitz B et al (2009) Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol 16:874–878
Wu CX, Lin GS, Lin ZX, Zhang JD, Liu SY, Zhou CF (2015) Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma. World J Surg Oncol 13:97
Mangiola A, De Bonis P, Maira G et al (2008) Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 113:841–846
Ruiz‐Ontañon P, Orgaz JL, Aldaz B et al (2013) Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma‐initiating cells that infiltrate peritumoral tissue. Stem Cells 31:1075–1085
Jain R, Poisson LM, Gutman D et al (2014) Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology 272:484–493
Nguyen TB, Cron GO, Perdrizet K et al (2015) Comparison of the diagnostic accuracy of DSC- and dynamic contrast-enhanced MRI in the preoperative grading of astrocytomas. Am J Neuroradiol 36:2017–2022
Aref M, Chaudhari AR, Bailey KL, Aref S, Wiener EC (2008) Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates. Magn Reson Imaging 26:1279–1293
Harrer JU, Parker GJ, Haroon HA et al (2004) Comparative study of methods for determining vascular permeability and blood volume in human gliomas. J Magn Reson Imaging 20:748–757
Haris M, Gupta RK, Singh A et al (2008) Differentiation of infective from neoplastic brain lesions by dynamic contrast-enhanced MRI. Neuroradiology 50:531–540
Choi HS, Kim AH, Ahn SS et al (2013) Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI. Korean J Radiol 14:487–492
Tofts PS, Berkowitz B, Schnall MD (1995) Quantitative analysis of dynamic Gd‐DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 33:564–568
Ingrisch M, Dietrich O, Attenberger UI et al (2010) Quantitative pulmonary perfusion magnetic resonance imaging: influence of temporal resolution and signal-to-noise ratio. Invest Radiol 45:7–14
Sourbron S (2010) Technical aspects of MR perfusion. Eur J Radiol 76:304–313
Acknowledgements
This study was supported by a grant from the Korea Health Care Technology R&D Projects, the Korean Ministry for Health, Welfare and Family Affairs (HI13C0015) and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean Ministry of Science, ICT & Future Planning (MSIP) (NRF-2015M3A9A7029740) and by Project Code (IBS-R006-D1). We would like to acknowledge statistical consultation from the medical research collaborating centre at the Seoul National University College of Medicine/the Seoul National University Hospital.
The scientific guarantor of this publication is Seung Hong Choi. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. No complex statistical methods were necessary for this paper. Institutional review board approval was obtained. Written informed consent was waived by the institutional review board. No study subjects or cohorts have been previously reported. Methodology: retrospective, case-control study, performed at one institution.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, R., Choi, S.H., Yun, T.J. et al. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. Eur Radiol 27, 1176–1185 (2017). https://doi.org/10.1007/s00330-016-4464-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-016-4464-6